Published in Lancet on June 06, 1987
CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci U S A (1988) 4.67
Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc Natl Acad Sci U S A (1988) 2.60
Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol (2011) 2.53
Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar J (2009) 1.72
Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci (2011) 1.70
Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg (2012) 1.62
Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS One (2008) 1.56
Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. J Exp Med (1990) 1.46
Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci U S A (1992) 1.37
Evaluation of an in vitro assay aimed at measuring protective antibodies against sporozoites. Bull World Health Organ (1990) 1.30
Restricted or absent immune responses in human populations to Plasmodium falciparum gamete antigens that are targets of malaria transmission-blocking antibodies. J Exp Med (1989) 1.27
NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect Immun (1996) 1.20
Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. J Exp Med (1994) 1.20
Expression and immune recognition of the conserved MSP4 outer membrane protein of Anaplasma marginale. Infect Immun (1993) 1.17
Protective immunity induced with the RTS,S/AS vaccine is associated with IL-2 and TNF-α producing effector and central memory CD4 T cells. PLoS One (2011) 1.15
Evidence for a 6.5-day minimum exoerythrocytic cycle for Plasmodium falciparum in humans and confirmation that immunization with a synthetic peptide representative of a region of the circumsporozoite protein retards infection. J Clin Microbiol (1989) 1.07
Pre-erythrocytic malaria vaccines: identifying the targets. Expert Rev Vaccines (2012) 1.07
Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect Immun (2004) 1.07
Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A. Infect Immun (1992) 1.05
Resistance to Plasmodium chabaudi in B10 mice: influence of the H-2 complex and testosterone. Infect Immun (1988) 1.04
Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Infect Immun (1996) 1.03
Liposomes, lipid A, and aluminum hydroxide enhance the immune response to a synthetic malaria sporozoite antigen. Infect Immun (1988) 1.03
Roles of the amino terminal region and repeat region of the Plasmodium berghei circumsporozoite protein in parasite infectivity. PLoS One (2012) 1.03
Enhanced epitopic response to a synthetic human malarial peptide by preimmunization with tetanus toxoid carrier. Infect Immun (1987) 1.02
Molecular dissection of the human antibody response to the structural repeat epitope of Plasmodium falciparum sporozoite from a protected donor. Malar J (2004) 1.01
Malaria vaccine development. Clin Microbiol Rev (1994) 1.01
Synthetic low-toxicity muramyl dipeptide and monophosphoryl lipid A replace Freund complete adjuvant in inducing growth-inhibitory antibodies to the Plasmodium falciparum major merozoite surface protein, gp195. Infect Immun (1991) 1.00
Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen. Infect Immun (1998) 0.98
Human T cells recognize polymorphic and non-polymorphic regions of the Plasmodium falciparum circumsporozoite protein. EMBO J (1988) 0.97
The March Toward Malaria Vaccines. Am J Prev Med (2015) 0.96
Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine (2015) 0.95
Successful human infection with P. falciparum using three aseptic Anopheles stephensi mosquitoes: a new model for controlled human malaria infection. PLoS One (2013) 0.95
The march toward malaria vaccines. Vaccine (2015) 0.95
Evidence for diversity of Plasmodium falciparum sporozoite surface antigens derived from analysis of antibodies elicited in humans. Infect Immun (1990) 0.95
Circumsporozoite antibodies and falciparum malaria incidence in children living in a malaria endemic area. Bull World Health Organ (1988) 0.92
Serodiagnosis of parasitic diseases. Clin Microbiol Rev (1991) 0.92
The circumsporozoite protein of Plasmodium: a mechanism of immune evasion by the malaria parasite? Bull World Health Organ (1990) 0.90
Active and passive immunization against Plasmodium yoelii sporozoites. Bull World Health Organ (1990) 0.90
Natural antibody responses against the non-repeat-sequence-based B-cell epitopes of the Plasmodium falciparum circumsporozoite protein. Infect Immun (1993) 0.89
Characterization of antibodies to sporozoites in Plasmodium falciparum malaria and correlation with protection. J Clin Microbiol (1988) 0.89
Human studies with synthetic peptide sporozoite vaccine (NANP)3-TT and immunization with irradiated sporozoites. Bull World Health Organ (1990) 0.89
Transformed Toxoplasma gondii tachyzoites expressing the circumsporozoite protein of Plasmodium knowlesi elicit a specific immune response in rhesus monkeys. Infect Immun (1999) 0.89
Effect of carrier selection on immunogenicity of protein conjugate vaccines against Plasmodium falciparum circumsporozoites. Infect Immun (1988) 0.88
Use of a tuberculin purified protein derivative--Asn-Ala-Asn-Pro conjugate in bacillus Calmette-Guérin primed mice overcomes H-2 restriction of the antibody response and avoids the need for adjuvants. Proc Natl Acad Sci U S A (1990) 0.88
Induction of protective immune responses by immunization with linear multiepitope peptides based on conserved sequences from Plasmodium falciparum antigens. Infect Immun (1998) 0.87
Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines. Malar J (2015) 0.87
Immunogenicity of well-characterized synthetic Plasmodium falciparum multiple antigen peptide conjugates. Infect Immun (2001) 0.86
Isolation and serological characterization of a Plasmodium vivax recombinant antigen. Infect Immun (1991) 0.86
Comparative analysis of ELISAs employing repetitive peptides to detect antibodies to Plasmodium falciparum sporozoites. Bull World Health Organ (1989) 0.85
Protective value of elevated levels of gamma interferon in serum against exoerythrocytic stages of Plasmodium falciparum. J Clin Microbiol (1991) 0.85
Differential antibody responses to Plasmodium falciparum and P. vivax circumsporozoite proteins in a human population. J Clin Microbiol (1989) 0.85
Antibody responses to Plasmodium falciparum and P. vivax sporozoites in areas with stable and unstable malaria. Bull World Health Organ (1990) 0.83
Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations. Malar J (2011) 0.82
Antimalarial drug resistance: An overview. Trop Parasitol (2016) 0.82
Association between HLA type and antibody response to malaria sporozoite and gametocyte epitopes is not evident in immune Papua New Guineans. Clin Exp Immunol (1989) 0.81
Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria. Clin Exp Immunol (1991) 0.81
Identification of a T-cell epitope on the circumsporozoite protein of Plasmodium vivax. Infect Immun (1990) 0.81
Serological responses to a soluble recombinant chimeric Plasmodium vivax circumsporozoite protein in VK210 and VK247 population. Malar J (2013) 0.80
Assessment in mice of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, P. falciparum. Immunology (1988) 0.80
The conformational restriction of synthetic vaccines for malaria. Bull World Health Organ (1990) 0.78
Tropical medicine. Postgrad Med J (1991) 0.77
Plasmodium vivax Controlled Human Malaria Infection - Progress and Prospects. Trends Parasitol (2016) 0.76
Infectivity of Plasmodium falciparum in Malaria-Naive Individuals Is Related to Knob Expression and Cytoadherence of the Parasite. Infect Immun (2016) 0.76
Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity. Malar J (2016) 0.75
Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes. Malar J (2017) 0.75
Molecular cloning and sequencing of the circumsporozoite protein gene from Plasmodium falciparum strain FCC-1/HN and expression of the gene in Mycobacteria. J Clin Microbiol (2001) 0.75
Status of malaria vaccine research. J R Soc Med (1989) 0.75
Cloning and expression of malaria and tuberculosis epitopes in mycobacterium bovis bacille calmette-guérin. Malays J Med Sci (2006) 0.75
Evidence implicating MHC genes in the immunological nonresponsiveness to the Plasmodium falciparum CS protein. Bull World Health Organ (1990) 0.75
Interferon-alpha and synthetic peptide malaria sporozoite vaccine in non-immune adults: antibody response after 40 weeks. Bull World Health Organ (1990) 0.75
Malaria vaccines. Arch Dis Child (1988) 0.75
Presence of a circumsporozoite-like protein in micronemes of blood-stage merozoites of malaria parasites. Bull World Health Organ (1990) 0.75
New use of BCG for recombinant vaccines. Nature (1991) 14.40
Cell lines derived from late embryonic stages of Drosophila melanogaster. J Embryol Exp Morphol (1972) 9.58
Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science (1984) 8.18
Diagnosis of malaria by detection of Plasmodium falciparum HRP-2 antigen with a rapid dipstick antigen-capture assay. Lancet (1994) 6.01
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet (2001) 5.01
Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet (1996) 4.90
Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. Science (2011) 4.72
Comparative testing of monoclonal antibodies against Plasmodium falciparum sporozoites for ELISA development. Bull World Health Organ (1987) 4.65
Cefotaxime-resistant Enterobacteriaceae isolates from a hospital in Warsaw, Poland: identification of a new CTX-M-3 cefotaxime-hydrolyzing beta-lactamase that is closely related to the CTX-M-1/MEN-1 enzyme. Antimicrob Agents Chemother (1998) 4.24
Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis (1997) 3.88
Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum. Science (1998) 3.83
Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg (1997) 3.61
Thrombospondin binds falciparum malaria parasitized erythrocytes and may mediate cytoadherence. Nature (1985) 3.53
Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science (1998) 3.46
Fluctuation analysis: the probability distribution of the number of mutants under different conditions. Genetics (1990) 3.32
Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg (1991) 3.31
Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science (1985) 3.24
Evolution of human influenza A viruses in nature: recombination contributes to genetic variation of H1N1 strains. Proc Natl Acad Sci U S A (1979) 3.13
Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet (1991) 3.01
Identification of Plasmodium falciparum-infected mosquitoes by a double antibody enzyme-linked immunosorbent assay. Am J Trop Med Hyg (1984) 3.00
Bloodmeal identification by direct enzyme-linked immunosorbent assay (ELISA), tested on Anopheles (Diptera: Culicidae) in Kenya. J Med Entomol (1988) 3.00
Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J Exp Med (1993) 2.96
The complexity of protective immunity against liver-stage malaria. J Immunol (2000) 2.92
Evolution of influenza A and B viruses: conservation of structural features in the hemagglutinin genes. Proc Natl Acad Sci U S A (1982) 2.86
In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J Clin Invest (1993) 2.84
Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum. Science (1985) 2.78
Variation of influenza A, B, and C viruses. Science (1982) 2.75
Plasmodium falciparum incidence relative to entomologic inoculation rates at a site proposed for testing malaria vaccines in western Kenya. Am J Trop Med Hyg (1994) 2.73
Circumsporozoite protein heterogeneity in the human malaria parasite Plasmodium vivax. Science (1989) 2.59
Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci U S A (1994) 2.58
An analysis of T cell responsiveness in Indian kala-azar. J Immunol (1987) 2.56
Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis (1997) 2.55
Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis (2001) 2.54
Field evaluation of enzyme-linked immunosorbent assays for Plasmodium falciparum and Plasmodium vivax sporozoites in mosquitoes (Diptera: Culicidae) from Papua New Guinea. J Med Entomol (1987) 2.45
Expression of Plasmodium falciparum circumsporozoite proteins in Escherichia coli for potential use in a human malaria vaccine. Science (1985) 2.44
The ecological role of bacteriocins in bacterial competition. Trends Microbiol (1999) 2.42
Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med (1990) 2.41
A novel type of AmpC beta-lactamase, ACC-1, produced by a Klebsiella pneumoniae strain causing nosocomial pneumonia. Antimicrob Agents Chemother (1999) 2.40
Knob-positive and knob-negative Plasmodium falciparum differ in expression of a strain-specific malarial antigen on the surface of infected erythrocytes. J Exp Med (1984) 2.38
Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. Virology (1983) 2.32
Infectivity to mosquitoes of Plasmodium falciparum clones grown in vitro from the same isolate. Trans R Soc Trop Med Hyg (1984) 2.31
Doxycycline therapy for leptospirosis. Ann Intern Med (1984) 2.29
Complete nucleotide sequence of the influenza A/PR/8/34 virus NS gene and comparison with the NS genes of the A/Udorn/72 and A/FPV/Rostock/34 strains. Nucleic Acids Res (1980) 2.25
Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. N Engl J Med (1984) 2.24
Sporadic occurrence of zoonotic swine influenza virus infections. J Clin Microbiol (1984) 2.24
Authentication of artemether, artesunate and dihydroartemisinin antimalarial tablets using a simple colorimetric method. Trop Med Int Health (2001) 2.22
Efficient expression of influenza virus NS1 nonstructural proteins in Escherichia coli. Proc Natl Acad Sci U S A (1983) 2.19
Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J Immunol (1984) 2.18
Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. Science (1987) 2.17
Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. J Exp Med (1996) 2.15
Blood-feeding patterns of Aedes aegypti (Diptera: Culicidae) collected in a rural Thai village. J Med Entomol (1993) 2.13
Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science (1987) 2.11
Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg (1986) 2.09
Properties of mouse leukemia viruses. VII. The major viral glycoprotein of friend leukemia virus. Isolation and physicochemical properties. Virology (1974) 2.09
Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. Science (1989) 2.09
Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science (1988) 2.09
Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. J Exp Med (1990) 2.09
A shotgun optical map of the entire Plasmodium falciparum genome. Nat Genet (1999) 2.04
Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics (1992) 2.02
Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J Infect Dis (1998) 2.00
Malaria: host-defense mechanisms and complications. Ann Intern Med (1970) 2.00
An estimation of the number of malaria sporozoites ejected by a feeding mosquito. Trans R Soc Trop Med Hyg (1990) 2.00
Characterization of Plasmodium falciparum sporozoite surface protein 2. Proc Natl Acad Sci U S A (1992) 2.00
Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Science (1991) 1.94
Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci U S A (1998) 1.93
IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. J Immunol (1999) 1.92
Failure of chloroquine in human babesiosis (Babesia microti): case report and chemotherapeutic trials in hamsters. Ann Intern Med (1978) 1.90
Malaria rapid diagnostic devices: performance characteristics of the ParaSight F device determined in a multisite field study. J Clin Microbiol (2001) 1.90
Human malaria transmission studies in the Anopheles punctulatus complex in Papua New Guinea: sporozoite rates, inoculation rates, and sporozoite densities. Am J Trop Med Hyg (1988) 1.89